NCT07287098 2026-03-16
preEMBER
Eli Lilly and Company
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT05307705 2026-03-02
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07410559 2026-02-18
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT05514054 2026-01-29
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04647487 2025-11-12
EMBER-2
Eli Lilly and Company
Phase 1 Completed
NCT07191717 2025-11-10
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05509790 2025-04-18
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
Eli Lilly and Company
Phase 1 Active not recruiting